Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Pilot trial assessing tolerability and effect of SYL1001 in patients with ocular pain
2012-001177-93Phase 2Completed
- Sponsor
- Sylentis
- Start
- Jul 2012
- Modality
- Vaccine mRNA → mRNA Therapeutics → RNA Therapeutics → Nucleic Acid Therapeutics, Chemically Modified siRNA → Small Interfering RNA (siRNA) → Small RNA Therapeutics → RNA Therapeutics → Nucleic Acid Therapeutics, Conjugated siRNA → Small Interfering RNA (siRNA) → Small RNA Therapeutics → RNA Therapeutics → Nucleic Acid Therapeutics
- Countries
- 1
01
Overview
Phase 2, single-arm trial of tivanisiran in dry eye syndrome (DED) and Ocular pain is not a disease; it is a symptom. The canonical disease entity most closely related to persistent, unexplained ocular pain is "ocular neuropathic pain" or "neuropathic ocular pain", sponsored by Sylentis. Primary endpoints: Analgesic effect on ocular pain and Ocular tolerability. Started Jul 2012; status: completed.
02
Drugs
tivanisiran
03
Conditions
dry eye syndrome (DED)Ocular pain is not a disease; it is a symptom. The canonical disease entity most closely related to persistent, unexplained ocular pain is "ocular neuropathic pain" or "neuropathic ocular pain".
Beyond the preview
Go deeper on 2012-001177-93.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2012-001177-93.